The Europe Tranexamic Acid market was valued at US$ 245.6 million in 2024 and is projected to reach US$ 345.4 million by 2030, at a CAGR of 5.8%
Tranexamic Acid is a synthetic amino acid derivative used as an antifibrinolytic medication. This pharmaceutical compound effectively controls bleeding in various clinical settings. Modern formulations include various delivery systems and improved stability profiles.
Healthcare leads with 55% market share, followed by pharmaceuticals (30%) and research (8%). Germany leads with 35% share. Clinical applications expanded 42% since 2022. R&D reached
